PPTA members produce approximately 80 percent of the plasma protein therapies used in the United States today and more than 60 percent worldwide.
Ethical Considerations in Compensated Plasma Donation +
PPTA's standards programs are cited in "Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products," in Transfusion. This Commentary concludes that there is no ethical basis for banning compensated plasma donation. Click here for the full article.Read More
Zika Virus and Plasma Protein Therapies +
Updated Sept. 8, 2016
Recent scientific and public press reports have heightened awareness of the emergence of Zika virus (ZIKV) in the Americas1, 2 and the causal relationship between prenatal ZIKV infection and microcephaly and other severe fetal brain defects3, 4.Read More
FDA Request to Cease Blood Collection in Florida +
PPTA is aware of the recent request by the FDA that blood establishments in Dade and Broward counties in the State of Florida cease blood collection. This request has been made as a “prudent measure” because State health officials are investigating a number of Zika infections that are not associated with travel to Zika-affected areas and may represent local transmission of the Zika virus.Read More